Ews have assessed research in advanced thyroid cancer30 and RAIrefractory DTC.22 We also did a PubMed literature search on 19 December 2013, using the terms “clinical trial, phase ii” [Publication Type] AND “thyroid neoplasms” [MeSH Terms] (no date restriction). This yielded 50 reports, of which only ten reported phase 2 studies of antiangiogenic agents in DTC. A equivalent search for phase three studies (“clinical trial, phase iii” [Publication Type]) yielded no benefits in DTC except for the present study design and style.25 Interpretation Previously, only phase two research of antiangiogenic agents have been reported in RAIrefractory DTC: axitinib,15 motesanib,21 pazopanib,13 sunitinib,14 vandetanib,19 and sorafenib.12,168,20 Hence, information within this setting are limited, and also the present phase 3 randomized study demonstrating significantly improved PFS with sorafenib versus placebo gives valuable clinical proof. These outcomes recommend that sorafenib represents a new remedy alternative for patients with progressive RAIrefractory DTC.Supplementary MaterialRefer to Net version on PubMed Central for supplementary material.AcknowledgementsThe authors thank the sufferers, their caregivers, and the investigators who participated within this study; the principal investigators are listed in Supplementary Appendix A. We also thank Emma Robinson (7.4 Limited, Oxford, UK), who provided healthcare writing help funded by Bayer HealthCare Pharmaceuticals. This study was supported by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary. Funding This operate was funded by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary. Conflicts of interest MSB has received consultancy fees/honorarium and study help from Bayer HealthCare Pharmaceuticals; consultancy costs and analysis support from Exelixis; consultancy costs from Onyx Pharmaceuticals; and analysis help from Eisai, Novartis, and Roche/Genentech.BuyEthyl 2-diazo-3-oxobutanoate CMN, RP, and YKS have received investigation help from Bayer HealthCare Pharmaceuticals.Formula of Pyrazine-2,3-diamine BJ has received honorarium and analysis support from Bayer HealthCare Pharmaceuticals; consultancy fees/ honorarium from AstraZeneca and Sobi; and honorarium from Eisai, Ipsen, Novartis, OxiGene, Pfizer, Roche, and Sanofi.PMID:24120168 RE has received consultancy fees/honorarium and study assistance from Bayer HealthCare Pharmaceuticals; and consultancy fees/honorarium from AstraZeneca and Genzyme. SS has received consultancy costs and analysis assistance from Bayer HealthCare Pharmaceuticals; and consultancy costs from Amgen, Celgene, Genomic Overall health, Roche, and Sanofi Aventis.Lancet. Author manuscript; offered in PMC 2015 March 19.Brose et al.Web page 10 LB has received consultancy charges and analysis assistance from Bayer HealthCare Pharmaceuticals; and consultancy fees from AstraZeneca. CF has received consultancy fees/honorarium and investigation assistance from Bayer HealthCare Pharmaceuticals; consultancy costs from AstraZeneca, SanofiAventis, and Sobi; plus a grant from Roche. FP has received honorarium and investigation help from Bayer HealthCare Pharmaceuticals. SIS has received study assistance from Bayer HealthCare Pharmaceuticals; consultancy fees/honorarium and research support from Amgen; consultancy fees/honorarium from AstraZeneca, Eisai, Exelixis, Lilly, NovoNordisk, and Veracyte; investigation assistance from Genzyme and Pfizer; and consultancy fees/honorarium from Onyx and Roche. JWAS has received honorarium and study support from Bayer HealthCare Phar.